Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ('Listing Regulations') - Transcript of Conference Call with Investors/Analysts Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Conference Call on the financial results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2022 Piramal Pharma Ltd - 543635 - Report Of The Auditors On Financial Results For The Quarter And Half Year Ended 30Th September, 2022.
In continuation to our financial results for the quarter and half year ended 30th September, 2022 filed with the stock exchanges after the Board Meeting held yesterday i.e. 08th November, 2022, please find attached independent auditor's reports on these financial results with Unique Document Identification Number. Q2FY23 Quarterly Result Announced for Piramal Pharma Ltd.
Piramal Pharma announced Q2FY23 results: Revenue from operation grew by 11% to Rs 3,202 crore versus Rs 2,889 crore in H1FY22 CDMO business grew by 12% YoY Complex Hospital Generic business grew by 11% YoY India's Consumer Healthcare business grew by 12% YoY Normalised EBITDA in H1FY23 was Rs 376 crore with EBITDA margin of 12% Capital Expenditure for H1FY23 was Rs 427 crore Successfully cleared 22 regulatory inspections and 111 customer audits in H1FY23 Released Piramal Pharma Sustainability Report FY22 Nandini Piramal, Chairperson, Piramal Pharma Ltd, said, “We announce our first results post demerger as an independent and focused pharma company. Over the last 10 years, we have made several strategic choices that have helped nurture and scale our business and establish Piramal Pharma (PPL) as a leading global pharmaceuticals player. For the quarter and half year that ended on September 2022, our business has delivered a resilient performance despite multiple internal and external challenges. We expect to deliver a much improved performance in second half of the current financial year. Historically we have had a greater skew of sales and profits in the second half of the year and this year is no different. We have a vision to grow all our businesses to significant scale over the medium term and have strong growth levers in place for each of them. We continue to make investments to drive growth in these businesses.” Result PDF Piramal Pharma Ltd - 543635 - Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended 30Th September, 2022
In compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Board of Directors of the Company at its meeting held today, i.e. 08th November, 2022, has inter alia, approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30th September, 2022. Piramal Pharma Ltd - 543635 - Board Meeting Outcome for Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended 30Th September, 2022
In compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Board of Directors of the Company at its meeting held today, i.e. 08th November, 2022, has inter alia, approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30th September, 2022. Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Intimation under Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 about the US FDA conducted a Good Manufacturing Practices (GMP) Inspection of Piramal Pharma Limited''s Riverview (Michigan, USA) facility. Piramal Pharma Ltd - 543635 - Intimation Of Schedule Of Analyst/ Institutional Investor Meetings Under The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Piramal Pharma Ltd - 543635 - Intimation Of The Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Intimation of the Contact details of Key Managerial Personnel as required under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')